OncoMatch/Clinical Trials/NCT06487481
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Is NCT06487481 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for adrenocortical carcinoma (acc).
Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of people with ACC survive 5 years after diagnosis. Objective: To test a new type of external beam RT before surgery in people with ACC. Eligibility: People aged 18 years and older with ACC that came back after treatment but may be safely removed with surgery. Design: Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of their heart function. They will have imaging scans. A small sample of tumor tissue may be collected if one is not available. They will undergo laparoscopy: Small incisions will be made in the abdomen so that a thin tube with a light and camera can be inserted to view the organs. RT comes from a machine that aims radiation at tumors. Participants will receive preoperative RT in daily fractions over approximately 2-3 weeks, followed by a planned surgical resection about 4 weeks after the completion of RT. Visits will last 30 to 60 minutes. Participants will undergo surgery to remove their tumors about 4 weeks after they finish RT. They will stay in the hospital 1 to 3 weeks after surgery. Participants will have follow-up visits for 10 years after surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: abdominal radiation therapy
Prior abdominal radiation therapy
Cannot have received: chemotherapy
Participants who have received chemotherapy ... within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 CTCAE
Cannot have received: immunotherapy
Participants who have received ... immunotherapy ... within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 CTCAE
Cannot have received: investigational therapy
Participants who have received ... investigational therapy ... within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 CTCAE
Cannot have received: radiotherapy
Participants who have received ... radiotherapy treatment within the last 4 weeks prior to starting treatment and/or have not recovered from toxicities to less than grade 2 CTCAE
Cannot have received: investigational therapy
Participants receiving other investigational therapies
Lab requirements
Blood counts
Hemoglobin >= 9.0 gm/dL; ANC >= 1,500/mm^3; Platelets >= 75,000/mm^3
Kidney function
Creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal calculated using eGFR
Liver function
AST and ALT <= 3 x ULN; Bilirubin <= 2 x ULN
Adequate organ function, including: Hemoglobin >= 9.0 gm/dL; ANC >= 1,500/mm^3; Platelets >= 75,000/mm^3; AST and ALT <= 3 x ULN; Bilirubin <= 2 x ULN; Creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal calculated using eGFR.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health Clinical Center · Bethesda, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06487481 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior abdominal radiation therapy, chemotherapy, immunotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 120 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify